Abs 1187 apremilast may have beneficial effects on cardiometabolic measures including reductions in HbA1c in severely obese patients and reductions in weight and dz activity improvements in PsO/ PsA outcomes across all BMI categories. #ACR22 @RheumNow https://t.co/fCdJxz2IDk https://t.co/mLnwKQs539

• Obesity Burden and Effects of Apremilast on Changes in Cardiometabolic Paramete…

Baker et al, Corevitas registry in 7000+ RA pts Pts w/ moderate pain HR 1.37 Pts w/ severe pain HR 1.42 more likely to switch to diff MOA b/tsDMARD Adjusted for confounders incl DA Time we address pain separately to spare MAOs in a lifelong disease! Abs#1590 #ACR22 @Rheumnow https://t.co/RP8Rb6bp9m

Metabolic disorders +diet patterns PsA 👉71.9% obese 👉metabolic synd 46.9% 👉dyslipid 41.9% 👉 HTN 37.5% Diet patterns assoc Dx activity ⬇️sugar⬇️fatigue⬇️PSAID score ⬆️whole fruit ⬇️SJC ⬆️unsat fats ⬆️enthesitis DIPSA -Med/DASH diet PsA ongoing #ACR22 @RheumNow Abst1007 https://t.co/cbggEw6IZp

#abs1601 #acr22 @rheumnow gender analysis of RCT 166 PsA pts on UST: F show ⬇️ response in resolution of pain, enthesitis, dactylitis& ACR response rates in both mono and MTXcombo groups. Unlike M, F seem not to benefit from UST+MTX combo for improvement of enthesitis& dactylitis https://t.co/a0uao6eWDO

BE COMPLETE study: Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment of PsA. No new safety signals. Abs#1599 @RheumNow #ACR22 https://t.co/iXj7wSRNeK

Abs 1507 at #ACR22 demonstrated that even a 6-month delay in PsA dx from symptom onset contributes to worse patient-reported outcomes measures on overall quality of life. @RheumNow https://t.co/qLOwE9rImz https://t.co/nacdjz5pCy

• Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Out…

The likelihood of a patient self-reporting LDA/REM and specificity of MDA score were unaffected by which MDA criteria were met. @DrLauraCoates et al, Abs 1496 #ACR22 @RheumNow https://t.co/xH70swdZZ0 https://t.co/Wct0emTaDt

• Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA C…

#Abs1260 #acr22 @rheumnow #acrbest Clincial&US eval 54 RA &18 PsA pts: Tenderness aasoctd w/radiographic progress in non-swollen jnts in PsA but not in RA. In tender non-swollen jnts in RA pts, baseline erosions& sonographic synovitis had significant impact on radio progression https://t.co/iqWvHiDeq8

RZB is efficacious in reducing signs and symptoms of PsA in patients, regardless of patterns of joint involvement Abs 1504 #ACR @AlexisOgdie @RheumNow https://t.co/AIEJbqrqBf https://t.co/kyiocs8TmL

• Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Exte…